What is Curebase?
Curebase is a San Francisco-based health-tech innovator dedicated to modernizing the clinical trial process. By leveraging remote study management techniques and cutting-edge software, the company empowers physicians to enroll patients directly within their local communities, effectively removing the geographical barriers that have historically hindered medical research. This decentralized approach not only accelerates the pace of clinical trials but also ensures a more diverse and representative patient population, ultimately driving higher quality medical innovations to market faster.
The company operates at the intersection of digital health and enterprise software, positioning itself as a critical infrastructure provider for pharmaceutical and biotech organizations. By reinventing the research lifecycle from the ground up, Curebase addresses the systemic inefficiencies in traditional trial models, offering a scalable solution that aligns with the industry's shift toward patient-centric care.
How much funding has Curebase raised?
Curebase has raised a total of $55M across 2 funding rounds:
Series A
$15M
Series B
$40M
Series A (2021): $15M with participation from Bold Capital, GGV Capital, and Xfund
Series B (2022): $40M led by Acrew Capital Management, BOLD Capital Group, World Innovation Lab, GGV Capital, Positive Sum, Industry Ventures, and Xfund
Key Investors in Curebase
GGV Capital
A global venture firm with a multi-stage, sector-focused approach, GGV Capital invests in high-growth companies across social, enterprise, and smart tech sectors.
Acrew Capital Management
Acrew Capital is a venture firm focused on long-term partnerships, providing strategic support to companies from early-stage development through growth-stage scaling.
Xfund
An early-stage venture capital firm that bridges the gap between academic research and transformative technology, supporting multidisciplinary innovators.
What's next for Curebase?
With the recent influx of capital, Curebase is poised to enter a new phase of operational maturity and market penetration. The strategic focus will likely center on enhancing its remote study management platform to support increasingly complex clinical protocols while maintaining rigorous data integrity standards. As the company scales, it will likely prioritize the expansion of its physician network and the integration of advanced analytics to further optimize patient recruitment and retention.
Looking ahead, the firm is well-positioned to capitalize on the growing demand for decentralized clinical trial (DCT) solutions. By maintaining its commitment to technological excellence and strategic partnerships, Curebase is set to redefine the standards of clinical research, ensuring that medical breakthroughs are accessible, efficient, and patient-focused in an increasingly digital-first healthcare environment.
